NSE · GLAXO · Pharmaceuticals
Glaxosmithkline Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹989 Cr with net profit ₹275 Cr — a 27.8% net margin, versus 26.11% the period before.
Shareholding
As of 2026-06-30
- Promoter75%
- Public12.41%
- FII4.79%
- DII7.8%
1,26,087 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.53× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Multinational · ranked #1 of 6 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Glaxosmithkline Pharmaceuticals Ltd.(this company) | ₹44,493 Cr | 160.15 | 19.62 | 45.69% | 27.11% |
| Pfizer Ltd. | ₹21,754 Cr | 108.86 | 5.18 | 17.19% | 28.61% |
| Sanofi Consumer Healthcare India Ltd. | ₹10,929 Cr | 161.19 | 31.14 | 76.46% | 28.01% |
| Sanofi India Limited | ₹7,876 Cr | 76.77 | 9.43 | 42.11% | 20.53% |
| Novartis India Ltd. | ₹3,950 Cr | 156.4 | 4.82 | 11.39% | 26.38% |
| Abbott India Limited | ₹464 Cr | 149.29 | 12.35 | 37.86% | 13.6% |
AI analysis
AI-generated · google/gemini-2.5-flashGlaxosmithkline Pharmaceuticals Ltd. is listed with a market capitalization of Rs 42463 Cr. The company reported a revenue growth of 1.93% and a profit margin of 27.11%. The promoter holding is 75%, with no pledged shares. The debt-to-equity ratio stands at 0.01.
Positives
- +The company's debt-to-equity ratio is low at 0.01.
- +Return on capital employed (ROCE) is high at 61.23%.
- +Return on equity (ROE) is 45.69%.
- +Promoter holding of 75% is stable, with no pledged shares reported.
Negatives
- −Revenue growth for the latest period is 1.93%, which is modest.
- −The P/E ratio is high at 152.84.
- −Promoter shareholding has remained static at 75% over several periods, indicating no recent increase in promoter commitment.
- −Foreign institutional investor (FII) holding has decreased from 1.6037% in June 2018 to 4.7869% in June 2026 when compared to March 2026 holding of 1.6037% to 4.7869% in June 2026.
Financial performance
For the fiscal year ending March 2026, Glaxosmithkline Pharmaceuticals Ltd. reported a revenue of Rs 3967.0348 Cr and a net profit of Rs 1035.9824 Cr. Quarterly revenue for March 2026 was Rs 995.3 Cr, with a net profit of Rs 277.86 Cr. The company's highest quarterly revenue in the provided data was Rs 1041.26 Cr in December 2025.
Profitability & returns
Glaxosmithkline Pharmaceuticals Ltd. demonstrates a return on equity (ROE) of 45.69% and a return on capital employed (ROCE) of 61.23%. The company's earnings per share (EPS) for the year ending March 2026 was Rs 61.15. The profit margin stands at 27.11% in the latest available data.
Balance sheet
The company has a book value of Rs 133.85. Glaxosmithkline Pharmaceuticals Ltd. maintains a low debt-to-equity ratio of 0.01, indicating minimal reliance on borrowed funds. There are no reported pledged shares by the promoters.
Ownership & pledges
As of June 30, 2026, the promoter holding in Glaxosmithkline Pharmaceuticals Ltd. is 75%. The public shareholding is 12.4124%. No shares are reported to be pledged by the promoters.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Glaxosmithkline Pharmaceuticals Ltd.share price & fundamentals